US Pre-Market SEC Filings Roundup — July 24, 2026

23-07-2026

Sr. Vice President TENG CHIN-CHI sold 1,968 Common Stock at $339.05 (~$667K). 11 transactions reported in total. TENG CHIN-CHI holds 141,781 shares after the transaction. Trades executed under a Rule 10b5-1 plan.

• · Sr. Vice President TENG CHIN-CHI exercised/converted 1,000 Common Stock at $202.94 (~$203K)
• · Sr. Vice President TENG CHIN-CHI sold 720 Common Stock at $335.70 (~$242K)
• · Sr. Vice President TENG CHIN-CHI sold 252 Common Stock at $336.71 (~$84.9K)
• · Sr. Vice President TENG CHIN-CHI sold 200 Common Stock at $337.78 (~$67.6K)
• · Sr. Vice President TENG CHIN-CHI sold 1,968 Common Stock at $339.05 (~$667K)
• · Sr. Vice President TENG CHIN-CHI sold 200 Common Stock at $340.70 (~$68.1K)
• · Sr. Vice President TENG CHIN-CHI sold 440 Common Stock at $342.15 (~$151K)
• · Sr. Vice President TENG CHIN-CHI sold 241 Common Stock at $342.98 (~$82.7K)

23-07-2026

Dominic Paul Allen filed a Schedule 13G with the SEC on July 23, 2026, disclosing beneficial ownership of 1,296,187 shares of Rare Earths Americas, Inc. common stock, representing a 6.5% stake. The shares are held by Mr. Allen as Trustee for The Westoz Services A/C, an Australian trust over which he has sole voting and investment power.

• · The filing is a Schedule 13G (not 13D), indicating a passive investment intent.
• · Mr. Allen has sole voting power and sole dispositive power over all 1,296,187 shares.
• · The trust is based in Australia (Leabrook, South Australia).
• · The company's common stock has a par value of $0.0001 per share.
• · The filing date is July 23, 2026, with an event date of May 7, 2026.

23-07-2026

RA Capital Management, L.P. and affiliated entities filed a Schedule 13D/A on July 23, 2026, disclosing aggregate beneficial ownership of 18,415,956 shares of Artiva Biotherapeutics, Inc. (ARTV), representing 37.9% of the outstanding common stock. The filing details a series of open-market purchases by the RA Capital Healthcare Fund between June 16 and July 23, 2026, totaling approximately 604,331 shares at weighted average prices ranging from $8.88 to $9.96 per share. While the Fund increased its stake, it holds pre-funded warrants for 2,170,138 shares that are currently blocked from exercise due to a 9.99% beneficial ownership limitation.

• · The Fund's open-market purchases occurred on 10 separate trading days between June 16 and July 23, 2026, with prices ranging from $8.62 to $10.00 per share.
• · The weighted average purchase price per share increased from $8.88 in late June to $9.96 by July 23, 2026.
• · The pre-funded warrants for 2,170,138 shares are subject to a Beneficial Ownership Blocker that prevents exercise if it would cause the Fund and its affiliates to own more than 9.99% of the outstanding common stock.
• · The Fund, Nexus Fund, and Nexus Fund III have delegated voting and investment power to RA Capital, which cannot be revoked on less than 61 days' notice.
• · No other person is known to have the right to receive dividends or proceeds from the sale of the reported shares.

23-07-2026

Chief Operating Officer McManus Matt sold 2,109 Common Stock at $0.45 (~$949). McManus Matt holds 382,879 shares after the transaction.

• · Chief Operating Officer McManus Matt sold 2,109 Common Stock at $0.45 (~$949)

23-07-2026

Director Kim Vyacheslav sold 9,371 American Depositary Shares, no par value at $87.03 (~$816K). 5 transactions reported in total. Trades executed under a Rule 10b5-1 plan.

• · Director Kim Vyacheslav sold 6,380 American Depositary Shares, no par value at $88.39 (~$564K)
• · Director Kim Vyacheslav sold 368 American Depositary Shares, no par value at $88.93 (~$32.7K)
• · Director Kim Vyacheslav sold 9,371 American Depositary Shares, no par value at $87.03 (~$816K)
• · Director Kim Vyacheslav sold 2,439 American Depositary Shares, no par value at $87.72 (~$214K)
• · Director Kim Vyacheslav sold 580 American Depositary Shares, no par value at $88.77 (~$51.5K)

23-07-2026

CEO and Chairman Vanderhook Timothy sold 5,000 Class A Common Stock at $11.03 (~$55.2K). Vanderhook Timothy holds 4,304 shares after the transaction. Trades executed under a Rule 10b5-1 plan.

• · CEO and Chairman Vanderhook Timothy sold 3,196 Class A Common Stock at $11.70 (~$37.4K)
• · CEO and Chairman Vanderhook Timothy sold 5,000 Class A Common Stock at $11.03 (~$55.2K)
• · CEO and Chairman Vanderhook Timothy sold 4,304 Class A Common Stock at $10.47 (~$45.1K)

22-07-2026

Greenbacker Renewable Energy Co LLC has entered into a definitive merger agreement with MN8 Energy Holdings LLC and its subsidiary, under which MN8 will acquire Greenbacker for a base purchase price of $375 million. Shareholders can elect to receive cash, MN8 common units, or a mixed consideration, subject to a maximum cash election amount of $125 million. The deal includes a $25 million holdback tied to project milestones and a $5 million expense reserve, with the transaction expected to close by early 2027.

• · Shareholders may elect cash, MN8 common units, or a 50/50 mixed consideration, subject to proration if cash elections exceed $125M.
• · The $25M holdback is contingent on a specified project achieving 'In Service' status by December 31, 2026.
• · If closing occurs on or after January 15, 2027, the full earned holdback is paid at closing with no post-closing additional consideration.
• · All outstanding Company RSUs and PSUs will fully vest and convert into mixed consideration at closing.
• · Greenbacker has the right to designate one director to the Holdings board until an IPO or alternative liquidity transaction.
• · The MN8 common units issued will be subject to transfer restrictions and IPO lock-up, but no more restrictive than for other holders.

24-07-2026

Ecopetrol S.A. filed a Form 6-K with the SEC for the month of July 2026, signed by CFO Alfonso Camilo Barco. The filing is a routine foreign private issuer report with no specific financial results, operational updates, or material events disclosed in the provided content.

24-07-2026

Nan Fung Trinity (HK) Ltd filed its quarterly 13F-HR report with the SEC for the period ending June 30, 2026, disclosing 55 equity holdings with a total market value of approximately $1,012,751,794. The portfolio is diversified across sectors including biotechnology, technology, real estate, and ETFs, with top holdings by value including Advanced Micro Devices, Amcor PLC, and PPG Industries. No period-over-period comparison data is available in this filing, so performance trends cannot be assessed.

• · The portfolio includes 4 iShares ETFs (MSCI Indonesia, Core S&P Mid-Cap, International Select Dividend, MBS) and 2 SPDR ETFs (S&P Homebuilders, S&P 500 Dividend).
• · Largest single position by shares held is Geron Corp with 2,223,550 shares, followed by Savara Inc with 1,842,350 shares.
• · Biotechnology and pharmaceutical companies represent a significant portion of the holdings, including Abeona, Abivax, Avalo, Bicara, Biocryst, BridgeBio, Celcuity, Climb Bio, Geron, Immunome, Kura Oncology, Mirum, Protagonist, Savara, Scholar Rock, Trevi, UniQure, Vaxcyte, Vor BioPharma, and Xenon.
• · Real estate holdings include Alexandria Real Estate Equities, BXP, Empire State Realty Trust, Kilroy Realty, SL Green Realty, and Vornado Realty Trust.
• · Technology holdings include Advanced Micro Devices, Meta Platforms, NVIDIA, and JD.com.
• · All positions are listed with sole voting and dispositive power.

24-07-2026

Flagstar Bank reported second quarter 2026 net income attributable to common stockholders of $26 million ($0.06 per diluted share), up from $13 million ($0.03 per diluted share) in Q1 2026 and a net loss of $78 million ($0.19 per diluted share) in Q2 2025. The bank also announced a $250 million share repurchase program. While C&I loans grew 12% QoQ to $18.6 billion and total deposits increased $689 million, net interest income declined 1% QoQ to $440 million, non-accrual loans rose 5% to $123 million, and net charge-offs increased 28% to $100 million (0.66% of average loans vs. 0.52% in Q1 2026).

• · Adjusted net income attributable to common stockholders was $23 million ($0.05 per diluted share) in Q2 2026, excluding a $4 million gain on the Figure Investment.
• · For the six months ended June 30, 2026, net income attributable to common stockholders was $39 million ($0.08 per diluted share) vs. a net loss of $186 million ($0.45 per diluted share) in the prior year period.
• · Total assets increased $0.6 billion QoQ to $87.7 billion.
• · Total deposits increased $689 million QoQ, with core deposits growing $644 million and C&I lending-related deposits growing $706 million.
• · Wholesale borrowings (FHLB advances) declined $250 million to $9.9 billion.
• · C&I originations in Q2 2026 totaled $2.8 billion, with commitments of $4.2 billion.
• · Specialized Industries Banking loans increased $1,675 million (34%) QoQ; Corporate & Regional Commercial Banking increased $375 million (18%) QoQ.
• · Total multi-family and CRE portfolio declined $1.5 billion (4%) QoQ to $35.2 billion.
• · CRE par payoffs totaled $1.1 billion, unchanged from Q1 2026; 39% of payoffs were substandard.
• · Total NYC multi-family loans declined $677 million (5%) QoQ; NYC multi-family loans with >=50% rent-regulated units declined $338 million (4%) QoQ.
• · ACL coverage for multi-family loans with >=50% rent-regulated units was 2.87%.
• · Net interest margin was 2.13% in Q2 2026, down 2 bps QoQ; excluding the extra day in the quarter, NIM would have been 2.16%.
• · Average interest-earning assets decreased $0.3 billion (0.3%) QoQ.
• · Non-interest income increased 38% QoQ to $76 million, driven by the gain on the Figure Investment.
• · Total revenues increased 4% QoQ to $516 million.
• · Positive operating leverage of 7%.
• · CET1 capital ratio of 13.16% is at or above peer group levels.
• · Excess capital of $1.6 billion using low end of target CET1 range of 10.5%.
• · Book value per share of $18.31; tangible book value per share of $17.51; tangible book value per share adjusted for warrant exercise is $15.54.

24-07-2026

Woori Financial Group Inc. announced a resolution to cancel treasury shares acquired within the limits of profits available for dividends. The cancellation will reduce the total number of shares issued but will not reduce the company's paid-in capital. This action is typically viewed as a positive signal for shareholders as it can increase earnings per share.

• · The cancellation does not reduce paid-in capital because it involves treasury shares acquired within the limits of profits available for dividends.

24-07-2026

HSBC Holdings PLC has agreed to sell its Singapore life insurance subsidiary, HSBC Life (Singapore) Pte. Ltd., to Allianz for a consideration of S$2.7 billion (US$2.1 billion). The transaction is expected to close in the first half of 2027, subject to regulatory approval, and will generate a pre-tax gain of US$1.8 billion and an estimated 15 basis-point increase in CET1 ratio for HSBC. Upon completion, HSBC and Allianz will enter an exclusive 15-year bancassurance distribution agreement, with HSBC receiving an initial lump sum cash payment of S$0.2 billion (US$0.2 billion). HSBC reaffirms its commitment to Singapore as a key wealth and wholesale banking hub.

• · Completion expected in the first half of 2027, subject to regulatory approval.
• · HSBC will receive an initial lump sum cash payment of S$0.2 billion (US$0.2 billion) upon entering the distribution agreement.
• · HSBC reaffirms Singapore as a key international wealth and wholesale banking hub and a focus of investment and growth.

24-07-2026

MOGU Inc. filed its annual report for the fiscal year ended March 31, 2026, reporting a net income of RMB 3,220 thousand (US$466 thousand), a significant turnaround from net losses of RMB 66,959 thousand in FY2024 and RMB 60,573 thousand in FY2025. However, total revenues continued to decline, falling 11.2% YoY to RMB 125,432 thousand (US$18,184 thousand), driven by decreases in commission, financing solutions, and technology services revenues. The company also recorded a gain on deconsolidation of a subsidiary of RMB 36,909 thousand and fair value losses on crypto assets of RMB 3,789 thousand.

• · The company reported a gain on deconsolidation of a subsidiary of RMB 36,909 thousand in FY2026.
• · Fair value changes of crypto assets resulted in a loss of RMB 3,789 thousand in FY2026.
• · Cash and cash equivalents increased 62.9% to RMB 133,627 thousand as of March 31, 2026, from RMB 82,021 thousand a year earlier.
• · Total assets decreased 3.6% to RMB 826,911 thousand as of March 31, 2026.
• · The company held RMB 4,691 thousand in crypto assets as of March 31, 2026.
• · Loan receivables, net decreased to RMB 19,913 thousand as of March 31, 2026 from RMB 31,108 thousand a year earlier.
• · Net cash used in operating activities was RMB 47,417 thousand in FY2026.

24-07-2026

SoundHound AI, Inc. announced it has received the final foreign investment clearance from Bulgarian authorities for its proposed acquisition of LivePerson, Inc., satisfying all regulatory approval conditions for the merger. The transaction remains subject to other closing conditions, including LivePerson stockholder approval, before the merger can be consummated.

• · Clearance was received from Italian and Canadian regulatory authorities on June 25, 2026.
• · Clearance was received from the German regulatory authority on June 29, 2026.
• · Clearance was received from the United Kingdom regulatory authority on July 1, 2026.
• · The final foreign investment clearance from Bulgaria was received on July 20, 2026.
• · The merger is structured as two sequential mergers: First Merger and Second Merger.
• · The merger agreement is an Amended and Restated Merger Agreement dated July 2, 2026.

24-07-2026

ICICI Bank Limited, acting through its IFSC Banking Unit, has priced USD 1 billion in Senior Unsecured Fixed Rate Notes under its USD 7.5 billion Global Medium Term Note Programme. The 5-year notes carry a coupon of 5.459% and will be listed on exchanges in India and Singapore. The net proceeds will be used for general corporate purposes.

• · The Notes are 144A/RegS Registered, Category 1, drawdown under the Programme.
• · Allotment date is July 30, 2026; maturity date is July 30, 2031.
• · Interest payment dates are 30 July and 30 January each year.
• · The Notes are unsecured and have no special rights or privileges.
• · The Notes are not offered for sale in the United States.

24-07-2026

China Yuchai International Ltd filed a Form 6-K on July 24, 2026, announcing it will release its unaudited first-half 2026 financial results on August 7, 2026. The filing includes a press release and is signed by President and Director Weng Ming Hoh. No financial results or performance data are provided in this filing.

• · The unaudited 2026 first-half financial results will be announced on August 7, 2026.
• · The filing is a routine foreign issuer report under Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934.
• · The company's principal executive office is at 16 Raffles Quay #26-00, Hong Leong Building, Singapore 048581.

24-07-2026

Glory Achievement Fund Limited, along with Bull Group Limited and BULL TRUST, filed Amendment No. 8 to Schedule 13D, disclosing that from June 25, 2026 through July 23, 2026, Glory Achievement Fund purchased 837,918 ADSs (representing 1,675,836 Class A ordinary shares) of Niu Technologies in the open market for approximately US$2.1 million. The Reporting Persons now beneficially own 65,693,947 Class A ordinary shares, representing 41.9% of the outstanding ordinary shares (assuming conversion of all Class B shares). The filing indicates the purchases were made for investment purposes and the group may continue to acquire or dispose of shares depending on market conditions.

• · The filing is Amendment No. 8 to the original Schedule 13D filed on December 7, 2023.
• · The Reporting Persons include Glory Achievement Fund Limited (Cayman Islands), Bull Group Limited (Cayman Islands), and BULL TRUST (Hong Kong).
• · The group's beneficial ownership percentage is based on 156,872,176 outstanding ordinary shares (141,650,156 Class A + 15,222,020 Class B) as of February 28, 2026.
• · Class B ordinary shares carry four votes per share, while Class A shares carry one vote per share.
• · No other transactions in the ordinary shares were effected by the Reporting Persons during the past 60 days except those described.

24-07-2026

GasLog Partners LP filed a Form 6-K with the SEC on July 24, 2026, attaching a press release regarding its financial results for the three-month period ended June 30, 2026. The filing is a routine foreign issuer report and does not contain any specific financial figures or performance data.

• · Filing is a Form 6-K for the month of July 2026
• · Commission File Number: 001-36433
• · Address: 69 Akti Miaouli, 18537 Piraeus, Greece
• · The attached press release covers results for the three-month period ended June 30, 2026

24-07-2026

Prudential Financial, Inc. filed an 8-K on July 24, 2026, disclosing that its Japanese subsidiaries issued a press release updating the remediation of previously disclosed employee misconduct in Japan. The filing provides an English translation of the press release but does not include any financial figures or performance metrics.

• · The press release was issued by three Japanese subsidiaries: PHJ, Prudential of Japan, and Gibraltar Life.
• · The misconduct was previously disclosed, and this update focuses on remediation progress.
• · The filing is under Regulation FD (Item 7.01) and is furnished, not filed, for SEC purposes.

24-07-2026

Galaxy Digital Inc. announced that its indirect wholly owned subsidiary, Galaxy Helios Data Centers II LLC, priced an offering of $3.507 billion aggregate principal amount of 9.875% Senior Secured Notes due 2031. The offering is expected to close on July 28, 2026, subject to market and customary conditions. The notes are being offered to qualified institutional buyers and non-U.S. persons under Rule 144A and Regulation S.

• · The notes are being offered under Rule 144A and Regulation S, not registered under the Securities Act.
• · The offering is subject to market and customary closing conditions.
• · The filing includes a cautionary note regarding forward-looking statements, including risks related to market conditions and the satisfaction of closing conditions.

24-07-2026

SK Telecom Co., Ltd. filed an amendment to its June 30, 2026 Form 6-K, updating the scheduled acquisition date for shares of SKHNPS to July 31, 2026, due to procedural progress. The amendment does not alter other aspects of the original filing.

• · Amendment No. 1 to Form 6-K filed July 24, 2026
• · Transaction involves acquisition of shares of SKHNPS
• · Original filing was furnished on June 30, 2026

24-07-2026

SeaTown Holdings Pte. Ltd. filed its quarterly 13F-HR report for the period ending June 30, 2026, disclosing a portfolio of 15 equity positions valued at approximately $166.4 million. The largest holdings by market value were NVIDIA Corporation ($18.8M), Advanced Micro Devices ($16.8M), and Take-Two Interactive Software ($15.9M), reflecting a strong tilt toward technology and semiconductor stocks. The filing shows no changes in share counts from the prior quarter, indicating a passive or hold strategy across all positions.

• · All 15 positions are held through a 'DFND' (discretionary fund) account with shared voting and dispositive power.
• · No options, warrants, or convertible securities were reported; all holdings are common stock.
• · The filing was signed by Ronald Ding, Head of Compliance, on July 23, 2026.
• · The report covers the period ending June 30, 2026, and was filed on July 24, 2026.

24-07-2026

AAR CORP. filed a Form 8-K on July 24, 2026, announcing a special performance-based restricted stock award for fiscal 2027. The award is designed to incentivize leadership through stock price performance goals and service-based vesting conditions. The filing includes forward-looking statements regarding potential achievement of those goals.

• · The special award covers fiscal year 2027 (ending May 31, 2027) and requires the recipient to satisfy both stock price goals and service-based vesting conditions.
• · The filing is dated July 23, 2026, and signed by Jessica A. Garascia as the authorized officer.
• · Exhibit 10.1 contains the form of the restricted stock agreement; Exhibit 104 provides the cover page interactive data file.
• · The company disclaims any obligation to update forward-looking statements, except as required by law.

24-07-2026

GSR Growth Investments LP and related entities filed a Schedule 13G/A exit filing, indicating they have ceased to be beneficial owners of 5% or more of Upexi, Inc. common stock. As of March 31, 2026, the group held an aggregate of approximately 3.08 million shares (4.2% of outstanding), down from a prior 5%+ stake. The filing reflects a reduction in ownership, not an increase.

• · This is an exit filing (Amendment No. 3) indicating the group no longer holds 5% or more of Upexi common stock.
• · GSR Growth Investments LP holds 705,882 shares (0.9947%) via convertible notes.
• · CNC Inversiones Ltd. holds 2,185,965 shares (3.11%) directly.
• · Total outstanding shares as of May 11, 2026: 70,261,828.

24-07-2026

AngloGold Ashanti PLC disclosed the voting results for a resolution to authorize off-market share repurchases at its general meeting. The resolution passed with 66.08% of votes in favor, while 33.92% were against, indicating significant shareholder opposition.

• · Broker non-votes were zero for this resolution.
• · The resolution was for authority to purchase own shares off-market.

24-07-2026

Perceptive Capital Solutions Corp (PCSC) completed its business combination with Freenome, Inc. on July 23, 2026, with Freenome as the accounting acquirer. The combined entity, renamed Freenome, Inc., issued 107.4 million pro forma common shares, with Freenome equity holders owning 63.4%. The transaction included a $240 million PIPE investment and conversion of a Roche convertible note. Pro forma cash and cash equivalents total $332.6 million, but the combined company has an accumulated deficit of $1.45 billion.

• · Freenome equity holders hold 63.4% of pro forma common stock; PCSC public stockholders 6.0%; sponsor shares 2.3%; PIPE investors 22.3%; Roche convertible note 6.0%.
• · Pro forma total assets: $722.6 million; total liabilities: $335.3 million.
• · Freenome historical accumulated deficit as of March 31, 2026 was $1.41 billion; pro forma accumulated deficit is $1.45 billion.
• · PCSC had $92.7 million in trust account before redemptions; $8.2 million redeemed for extension and $15.1 million at closing.
• · Freenome had $102.1 million in short-term marketable securities and $156.9 million in property and equipment as of March 31, 2026.

24-07-2026

News Corp disclosed on Form 8-K that it is authorized to repurchase up to $1 billion in aggregate of its Class A and Class B common stock under its existing stock repurchase program. The company provided copies of daily transaction disclosures made to the Australian Securities Exchange (ASX) as exhibits. The filing reiterates the company's intent to repurchase shares from time to time, subject to market conditions and other factors.

• · The repurchase program covers both Class A common stock (ticker NWSA) and Class B common stock (ticker NWS).
• · The company is required to provide daily transaction disclosures to the ASX under ASX rules.
• · The filing includes forward-looking statements regarding the company's intent to repurchase shares, subject to risks such as changes in stock price, market conditions, securities laws, and alternative investment opportunities.

24-07-2026

Blue Owl Technology Income Corp. reported an unregistered sale of 278,351 Class I shares for $2.7M as of July 1, 2026, and declared a monthly distribution of $0.074775 per share across all classes. The company's aggregate NAV was $2.7B as of June 30, 2026, with Class I shares showing mixed performance: a 1-month total net return of -0.7% and a 1-year return of 2.3%, while outperforming public credit indices since inception. The portfolio had $5.1B fair value in 173 companies with 0.82x net leverage.

• · The company's portfolio consists of 87.1% first lien debt investments, 3.9% second lien, 1.3% unsecured, 3.3% preferred equity, 1.9% specialty finance equity, 2.2% common equity, and 0.3% joint venture investments.
• · Top three industries by fair value: Application Software ($827M, 16.5%), Systems Software ($680M, 13.5%), Health Care Technology ($675M, 13.3%).
• · Average debt-to-equity leverage ratio during month-to-date ended June 30, 2026 was 0.78x.
• · Class S shares with max sales load: 1-month return -4.1%, 1-year return -2.0%.
• · Class D shares with max sales load: 1-month return -2.2%, 1-year return 0.5%.

24-07-2026

Blue Owl Credit Income Corp. filed an 8-K reporting the sale of 236,512 unregistered Class I shares for $2,147,527 as of July 1, 2026, under a private offering exempt from SEC registration. The filing also disclosed a monthly distribution of $0.070100 per share for all classes payable by August 31, 2026, and provided a performance update showing strong 1-month total net return of 30.0% for Class I shares, though longer-term returns are more moderate (1-year: 5.6%, 3-year: 9.6%). The company reported aggregate NAV of $18.4 billion as of June 30, 2026, with available liquidity of $12.0 billion and a net leverage of 0.89x debt-to-equity.

• · The company's portfolio consists of 87.0% first lien debt investments, 3.7% second lien debt, 1.2% unsecured debt, 0.4% specialty finance debt, 1.4% preferred equity, 1.4% common equity, 3.9% specialty finance equity, and 1.0% joint ventures.
• · Average debt-to-equity leverage ratio during month-to-date ended June 30, 2026 was 0.84x.
• · Of the $24,935M committed debt capacity, $17,090M was outstanding as of June 30, 2026.
• · The company has 6 revolving credit facilities ($3,900M committed, $592M drawn), 11 SPV asset facilities ($10,300M committed, $5,763M drawn), 9 CLOs ($3,562M committed and drawn), and 6 unsecured notes ($7,173M committed and drawn).
• · Of the $7.2B unsecured fixed rate leverage, $6.3B is hedged by interest rate swaps.
• · Top industry exposures by fair value: Healthcare providers and services (13.9%), Internet software and services (13.6%), Insurance (8.7%), Healthcare equipment and services (7.0%), Financial services (6.3%).
• · Class I NAV per share as of June 30, 2026: $9.08; Class D: $9.06; Class S: $9.05.
• · Class S shares carry a maximum upfront sales load of 3.5%, Class D 1.5%, Class I no sales load.
• · The monthly distribution for Class I is $0.070100 per share (net, no servicing fee), Class D $0.068176 (net after $0.001924 servicing fee), Class S $0.063567 (net after $0.006533 servicing fee).

24-07-2026

Versus Systems Inc. filed an 8-K on July 23, 2026, disclosing that it believes it has regained compliance with Nasdaq's minimum $2.5 million stockholders' equity requirement for continued listing. The company achieved this through a stock issuance to ASPIS Cyber Technologies (ACT) for $1.7 million and recognized $1.485 million in revenue from a renewed technology license agreement with ACT. However, Nasdaq cautioned that it will continue to monitor compliance and the company could face delisting if it fails to evidence compliance in its next periodic report.

• · Nasdaq issued a deficiency letter on April 29, 2026, for failing to maintain minimum $2.5M stockholders' equity as of December 31, 2025.
• · The stock purchase agreement with ACT was dated April 15, 2026, and consummated on June 26, 2026.
• · The technology license agreement renewal was executed on May 15, 2026, with monthly fees of $165,000 through at least January 31, 2027.
• · Pro forma total liabilities as of June 30, 2026, were $732,397, up from $459,340 on March 31, 2026.
• · Pro forma intangible assets increased to $1,263,000 from $936,000.

24-07-2026

Outlook Therapeutics, Inc. granted stock options to CEO Robert C. Jahr (100,000 options) and CFO Lawrence A. Kenyon (210,078 options) at an exercise price of $1.4304 per share, vesting on July 21, 2027. Additionally, the Compensation Committee approved cash bonuses of $420,000 for the CEO and $200,000 for the CFO, payable only if the FDA approves ONS-5010 (bevacizumab-vikg) by July 31, 2026. The awards recognize their contributions to the BLA process and the company's non-payment of 2025 annual bonuses.

• · The stock options were granted under the company's 2024 Equity Incentive Plan.
• · The options vest and become exercisable on July 21, 2027, subject to continued service.
• · The cash bonuses are contingent on FDA approval of ONS-5010 by July 31, 2026, and continued service through payment date.
• · The bonuses were awarded in part due to the company's non-payment of annual bonuses for 2025 service.

24-07-2026

Hashdex Asset Management Ltd. and CSC Delaware Trust Company entered into a Sixth Amended and Restated Trust Agreement for the Hashdex Nasdaq Crypto Index US ETF (NCIQ) on July 23, 2026, replacing the Fifth Amended and Restated Trust Agreement from January 20, 2026. The amended agreement updates the trust's governing structure, definitions, and operational procedures, including provisions for staking activities on eligible crypto assets like Ether. The filing is a routine administrative update to the trust's legal framework and contains no financial results or performance data.

• · The trust was formerly known as the Hashdex Nasdaq Crypto Index US ETF.
• · The agreement includes provisions for 'Eligible Staking Assets' and 'Net Staking Income' from staking activities.
• · The Index is the Nasdaq CME Crypto Settlement Price Index™ (NCIS) administered by the Index Provider (Nasdaq, Inc.).
• · The Calculation Agent is CF Benchmarks Limited.
• · The Partnership Representative is Bruno Melo Caratori (or his designee).
• · The trust is governed by the Delaware Statutory Trust Act.

24-07-2026

Scancell Holdings plc and Neuphoria Therapeutics Inc. announced an all-share merger in which Scancell will acquire Neuphoria. The combined company will operate as Scancell and list on Nasdaq under the symbol 'SCLT', while retaining Scancell's AIM listing. Alongside the merger, Scancell expects to secure up to $89 million in financing through a private placement ($39.1M), UK placing ($12.0M), retail offer ($3.0M), and debt financing ($25M from BlackRock). Existing Scancell shareholders will own 85.5% of the combined company, while Neuphoria shareholders will own 14.5%. The transaction is expected to close in late Q4 2026, subject to shareholder and regulatory approvals.

• · The combined company will apply to trade on Nasdaq under the symbol 'SCLT'.
• · Scancell's lead asset iSCIB1+ has fast-track designation from the FDA and demonstrated 77% Progression Free Survival at 22 months in the Phase 2 SCOPE study.
• · The Phase 3 iSCIB1+ primary readout is expected in H2 2028, with cash runway extending into 2029.
• · Neuphoria stockholders will receive Contingent Value Rights (CVRs) for potential future cash payments based on milestones from partnered assets, IP monetization, and Australian R&D tax credit.
• · The Merger Agreement may be terminated if not completed by 28 February 2027 (with possible 60-day extension if SEC has not declared F-4 effective).
• · Scancell does not intend to develop Neuphoria's non-partnered assets post-merger.
• · Lock-up agreements for 180 days post-Completion apply to directors and certain shareholders of both companies.
• · The Private Placement is conditional on EGM approval, Merger closing, and Nasdaq listing.
• · The UK Placing and Retail Offer are not conditional on the US Listing Transactions.
• · The Merger is conditional on Neuphoria's net cash at closing being at least $10 million.

24-07-2026

Hyliion Holdings Corp. announced on July 22, 2026, that it was awarded a cost-plus-fixed-fee contract by the Office of Naval Research (ONR) with a total value of approximately $42 million. The contract supports the HELMUR Megawatt Scale Power Generation Units program, covering design, development, and delivery of 2-megawatt and 3-megawatt units, with work expected to be completed by July 2029. This represents a significant non-dilutive funding source and validates Hyliion's technology for defense applications, though the contract carries no option periods and all funding is obligated upfront.

• · Contract is cost-plus-fixed-fee, reducing financial risk for Hyliion.
• · Funding obligated at award using FY2025 and FY2026 Navy RDT&E appropriations.
• · Work includes advancing core technology, developing alternative core components, reducing supply chain risk for magnets, and furthering additive manufacturing processes.
• · Contract awarded under Long Range Broad Agency Announcement N00014-25-S-B001.
• · No option periods; contract is a single 36-month base period.

24-07-2026

Healthy Extracts Inc. entered into a Securities Purchase Agreement on July 17, 2026, issuing a $258,750 promissory note to LABRYS FUND II, L.P. The note carries a 10% interest rate, a one-year maturity, and includes an original issue discount of $33,750, resulting in net proceeds of $225,000 (minus expenses). The note is convertible after 180 days at a discount to market price, and the company must make monthly amortization payments of $36,964.28 starting January 18, 2027, unless converted. The transaction was conducted as an unregistered sale of securities to an accredited investor.

• · The note may not be prepaid without the Holder's consent.
• · Conversion price is the lesser of $2.00 per share or 75% of the lowest closing bid price during the 15 trading days prior to conversion.
• · Monthly amortization payments of $36,964.28 begin January 18, 2027 and continue for six months.
• · The securities were issued in reliance on Section 4(a)(2) of the Securities Act to an accredited investor.

24-07-2026

Southside Bancshares reported Q2 2026 net income of $26.8 million ($0.90 EPS), up 23% YoY from $21.8 million ($0.72 EPS), driven by higher net interest income and noninterest income and lower expenses. However, linked quarter net interest income fell 0.6% to $57.3 million due to rising funding costs, and loan growth was modest at $3.4 million (0.1%). Asset quality remained strong with nonperforming assets at 0.11% of total assets, while deposits declined 7.0% YoY and 10.3% linked quarter, largely due to a sharp reduction in brokered deposits.

• · Classified loans totaled $260.1 million at June 30, 2026, down from $290.8 million at March 31, 2026 but up from $176.9 million at December 31, 2025.
• · Net charge-offs were $0.3 million in Q2 2026, compared to $0.9 million in Q2 2025 and $0.2 million in Q1 2026.
• · The company recorded a reversal of provision for credit losses for loans of $24,000 in Q2 2026, versus a provision of $0.7 million in Q2 2025 and $1.0 million in Q1 2026.
• · Securities decreased 3.0% linked quarter to $2.78 billion at June 30, 2026.
• · Estimated uninsured deposits were 42.8% of total deposits; excluding affiliate and public fund deposits, uninsured/collateralized deposits were 24.9%.
• · Noninterest bearing deposits represent approximately 22.8% of total deposits.
• · The company did not repurchase any common stock during Q2 2026; approximately 0.8 million shares remain available under the repurchase plan.
• · A Q2 2026 cash dividend of $0.36 per share was declared on May 6, 2026 and paid on June 1, 2026.
• · The effective tax rate was 17.6% in Q2 2026, down slightly from 17.8% in both Q2 2025 and Q1 2026.

24-07-2026

FG Imperii Acquisition Corp. filed its 10-Q for the quarter ended June 30, 2026, reporting net income of $1,948,659 for the three-month period and $3,347,053 for the six-month period. The company completed its IPO during the period, raising $227,500,000 from the sale of 22,750,000 units at $10 per unit (including over-allotment), and held $231,056,147 in its trust account as of June 30, 2026. However, the company reported a loss from operations of $59,219 for the quarter and $209,094 for the six-month period, and non-redeemable shareholders recorded a basic loss per share of $(0.12) for the six-month period.

• · The company had no revenue and reported a loss from operations of $209,094 for the six-month period.
• · Non-redeemable shareholders recorded a basic loss per share of $(0.12) for the six-month period and $(0.002) for the three-month period.
• · Total assets increased from $163,944 at December 31, 2025 to $232,042,352 at June 30, 2026, primarily due to the IPO proceeds held in trust.
• · The company had $1,202 in accounts payable and no promissory note outstanding as of June 30, 2026.
• · Net cash provided by operating activities was $3,314,026 for the six-month period.
• · The company issued 200,000 underwriter units and an additional 27,500 underwriter units due to over-allotment exercise.

24-07-2026

Intel reported a net loss of $11.0B for Q2 2026 (vs. $2.9B loss in Q2 2025) and a net loss of $14.8B for H1 2026 (vs. $3.7B loss in H1 2025). Revenue grew 25% YoY to $16.1B in Q2, driven by strong performance in both CCG (+?%) and DCAI (+?%), but the bottom line was severely impacted by $12.6B in interest and other charges (including a $13.6B mark-to-market loss on Escrowed Shares) and $170M in restructuring charges. Gross margin improved to 40.4% from 27.5% a year ago, while operating income swung to a positive $1.8B from a loss of $3.2B. However, net losses widened dramatically due to non-operating charges, and total equity fell from $126.4B to $103.1B.

• · Q2 2026 gross margin improved to 40.4% from 27.5% in Q2 2025.
• · Intel Products segment (CCG + DCAI) generated $4.8B operating income in Q2 2026, while Intel Foundry posted a $2.1B operating loss.
• · Interest and other, net swung to a $12.6B expense in Q2 2026 from a $95M expense in Q2 2025, primarily due to a $13.6B mark-to-market loss on Escrowed Shares.
• · Total debt increased to $50.5B (short-term $2.0B + long-term $48.5B) from $46.6B at year-end 2025.
• · Cash and cash equivalents declined to $12.9B from $14.3B at year-end 2025.
• · Goodwill decreased by $3.4B to $20.5B from $23.9B at year-end 2025.
• · Partner distributions and repurchase of subsidiary shares totaled $13.9B in H1 2026, significantly impacting equity.
• · H1 2026 capex of $6.2B was down 29% from $8.7B in H1 2025.
• · Operating cash flow improved to $8.1B in H1 2026 from $2.9B in H1 2025.